A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

The revenue for the cell therapy Carvykti and the EGFR-targeted lung cancer duo Rybrevant-Lazcluze contributed to double digit gains in oncology drug sales.

The company hopes to commercialize its tumor profiling assay after it secures $10 million via a share purchase agreement.

Debiopharm will take over development of the PKMYT1 inhibitor and advance it in combination with its WEE1 inhibitor in the MYTHIC trial.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.

While NICE recommended the drug for patients with at least one F508del mutation, Vertex struck a reimbursement deal with NHS England for a broader population.

An AI-based EGFR biomarker tool could preclude the need for a rapid PCR test in nearly half of advanced lung adenocarcinoma cases, a study has suggested.

The firm also said it would evaluate strategic alternatives for its animal health business and close a prostate cancer vaccine trial.

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

The firm said the agency cited chemistry, manufacturing, and controls issues in its complete response letter, but had no concerns about product quality.